All In MedTech

FDA Clearance Tracker · P200010-S027

Guardant360 CDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 10, 2026

Approved

Time to decision

209 days

Received Nov 13, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P200010-S027
Device name
Guardant360 CDx
Applicant location
Redwood City, CA
Received
Nov 13, 2025
Decided
Jun 10, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P200010

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval to include a companion diagnostic indication to identify patients with non-small cell lung cancer (NSCLC) harboring ERBB2/HER2 activating mutations (SNVs in exons 18-21 within the tyrosine kinase domain and exon 20 insertions) who are eligible for treatment with HERNEXEOS (zongertinib).

Source documents

Other decisions for Guardant Health, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.